Connect with us

Hi, what are you looking for?

Jewish Business News


Jim Cramer: Good Thing Allergan Didn’t Buy Salix

Jim Cramer

Salix Pharmaceuticals was considered as a potential buy by Allergan to ward off a hostile takeover by Valeant Pharmaceuticals and activist investor Bill Ackman. Jim Cramer pointed out on CNBC that it is fortunate for Allergan that they didn’t make this deal. Salix would have been a Trojan Horse of problems. It missed on earnings, the CFO resigned and now it is being investigated for mismanagement. “When the committee investigates you, something is very wrong.” Allergan’s stock has been performing well amid the takeover talk, but it would have been worse for Allergan if it had bought Salix to get out of the controversy.




You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.